Skip to main content

ORAGENICS INC

For the period ended Mar 31, 2025. Filed May 9, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 9, 2025

OGEN$0.34-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Deficit

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

Common Stock · Preferred Stock · Additional Paid In · Accumulated · Total Shareholders’
SharesAmountSharesAmountCapitalDeficitEquity
Balances at December 31, 202412,570,100$12,5707,488,692$—$216,561,717$(216,786,172)$(211,885)
Compensation expense relating to options————17,706—17,706
Compensation expense recapturerelating to options————(86,470)—(86,470)
Sale of Common Stock7,765,4847,765——2,626,425—2,634,190
Conversion of prefunded warrants to common stock1,139,7051,140————1,140
Issuance of Series G Preferred Stock——1,000,000————
Net loss—————(2,216,993)(2,216,993)
Balances at March 31, 202521,475,289$21,4758,488,692$—$219,119,378$(219,003,165)$137,688
Common Stock · Preferred Stock · Additional Paid In · Accumulated · Total Shareholders’
SharesAmountSharesAmountCapitalDeficitEquity
Balances at December 31, 20233,080,693$3,08116,955,692$1,592,723$207,790,604$(206,218,254)$3,168,154
Compensation expense relating to option issuances————69,344—69,344
Sale of Common Stock1,400,0001,399——1,837,2011,838,600
Net loss—————(2,450,833)(2,450,833)
Balances at March 31, 20244,480,693$4,48016,955,692$1,592,723$209,697,149$(208,669,087)$2,625,265
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.